Strategic partnerships Belharra has a high-profile collaboration with Sanofi and notable founders from Scripps Research and the Broad Institute, indicating openness to co-development and external validation. This suggests opportunities to propose scale-up collaborations, co-discovery programs, or access to their chemoproteomics platform for partner-driven targets.

C-suite growth Appointment of a new Chief Scientific Officer signals a focus on scientific leadership and potential shifts in research priorities. Engage at the executive level to align on target scouting, platform capabilities, and high-value target exploration for immuno-oncology, autoimmune, or proteome-wide ligand discovery.

Target expansion Their platform claims to identify drug candidates for any binding site, on any protein, in any state, across any cell type, enabling exploration of difficult-to-drug targets. Offer capabilities around target validation services, high-throughput chemoproteomics support, and specialized assay development for novel targets.

Funding traction With a Series A of $50M and subsequent notable financing and growth activities, Belharra is financially positioned for expansion and platform-scale collaborations. Propose multi-year discovery or platform access agreements, as well as sponsored research programs to accelerate pipeline generation.

Geographic and lab presence Headquartered in the San Francisco Bay Area with primary labs in San Diego, the company is positioned for regional collaboration across biotech hubs. Explore co-lab spaces, joint venture discussions, and access to talent pools for joint discovery initiatives or regional CRO partnerships.